M. Brent McHenry
About
M. Brent McHenry is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics.
According to data from OpenAlex, M. Brent McHenry has authored 42 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 25 papers in Pulmonary and Respiratory Medicine and 8 papers in Economics and Econometrics. Recurrent topics in M. Brent McHenry's work include Cancer Immunotherapy and Biomarkers (21 papers), Renal cell carcinoma treatment (20 papers) and Economic and Financial Impacts of Cancer (8 papers). M. Brent McHenry is often cited by papers focused on Cancer Immunotherapy and Biomarkers (21 papers), Renal cell carcinoma treatment (20 papers) and Economic and Financial Impacts of Cancer (8 papers). M. Brent McHenry collaborates with scholars based in United States, France and Germany. M. Brent McHenry's co-authors include David F. McDermott, Brian I. Rini, Robert J. Motzer, Elizabeth R. Plimack, Omid Hamid, Christian Kollmannsberger, Nizar M. Tannir, Kevin M. Chin, Howard I. Scher and Tomasz M. Beer and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Annals of Oncology.
In The Last Decade
M. Brent McHenry
42 papers receiving 2.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| M. Brent McHenry United States | 24 | 1.9k | 1.4k | 736 | 602 | 444 | 42 | 2.8k | ||
| Victoria Villaflor United States | 28 | 1.5k 0.8× | 1.2k 0.9× | 263 0.4× | 600 1.0× | 404 0.9× | 132 | 2.9k | ||
| Sebastiano Buti Italy | 26 | 1.1k 0.6× | 1.2k 0.9× | 275 0.4× | 690 1.1× | 485 1.1× | 210 | 2.2k | ||
| Guillermo de Velasco Spain | 27 | 1.3k 0.7× | 1.7k 1.3× | 239 0.3× | 910 1.5× | 621 1.4× | 113 | 2.6k | ||
| Pei He United States | 12 | 2.1k 1.1× | 1.4k 1.0× | 625 0.8× | 354 0.6× | 390 0.9× | 30 | 3.0k | ||
| Matthew A. Gubens United States | 30 | 3.4k 1.8× | 2.3k 1.7× | 754 1.0× | 565 0.9× | 524 1.2× | 100 | 4.3k | ||
| Brigitte Laguerre France | 25 | 972 0.5× | 1.8k 1.3× | 201 0.3× | 919 1.5× | 659 1.5× | 152 | 2.6k | ||
| Ryuichi Mizuno Japan | 28 | 926 0.5× | 1.2k 0.9× | 272 0.4× | 1.1k 1.8× | 526 1.2× | 205 | 2.6k | ||
| Davey B. Daniel United States | 19 | 2.2k 1.2× | 2.1k 1.5× | 362 0.5× | 538 0.9× | 688 1.5× | 82 | 3.3k | ||
| Wade T. Iams United States | 21 | 1.4k 0.7× | 718 0.5× | 459 0.6× | 806 1.3× | 514 1.2× | 95 | 2.2k | ||
| Stefan Diem Switzerland | 17 | 2.2k 1.2× | 629 0.5× | 625 0.8× | 294 0.5× | 219 0.5× | 31 | 2.6k |
Countries citing papers authored by M. Brent McHenry
Since
Specialization
Citations
This map shows the geographic impact of M. Brent McHenry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Brent McHenry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Brent McHenry more than expected).
Fields of papers citing papers by M. Brent McHenry
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by M. Brent McHenry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Brent McHenry. The network helps show where M. Brent McHenry may publish in the future.
Co-authorship network of co-authors of M. Brent McHenry
This figure shows the co-authorship network connecting the top 25 collaborators of M. Brent McHenry. A scholar is included among the top collaborators of M. Brent McHenry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Brent McHenry. M. Brent McHenry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Oh, D-Y., Ken Kato, Tobias Arkenau, et al.. (2023). LBA80 Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study. Annals of Oncology. 34. S1320–S1321.
2.
Oh, D-Y., H-T. Arkenau, Josep Tabernero, et al.. (2023). 139MO Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study. Annals of Oncology. 34. S1526–S1527.
3.
Motzer, Robert J., Nizar M. Tannir, David F. McDermott, et al.. (2021). 661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). Annals of Oncology. 32. S685–S687.
4.
Albigès, Laurence, Nizar M. Tannir, Mauricio Burotto, et al.. (2020). Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 5(6). e001079–e001079.
5.
Tannir, Nizar M., David F. McDermott, Bernard Escudier, et al.. (2020). Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology. 38(6_suppl). 609–609.
6.
McFarlane, Joshua J., Mark D. Kochenderfer, Mark R. Olsen, et al.. (2020). Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study. Clinical Genitourinary Cancer. 18(6). 469–476.e4.
7.
Grünwald, Viktor, Toni K. Choueiri, Brian I. Rini, et al.. (2019). Association between depth of response and overall survival: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214. Annals of Oncology. 30. v382–v383.
8.
Hammers, Hans J., Elizabeth R. Plimack, Jeffrey R. Infante, et al.. (2017). Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. Journal of Clinical Oncology. 35(34). 3851–3858.
9.
Zhao, Xiaochen, Satyendra Suryawanshi, Matthew Hruska, et al.. (2017). Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. Annals of Oncology. 28(8). 2002–2008.
10.
Escudier, Bernard, Nizar M. Tannir, David F. McDermott, et al.. (2017). CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups. Annals of Oncology. 28. v621–v622.
11.
Lebbé, Célèste, Jeffrey S. Weber, Michele Maio, et al.. (2014). Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Annals of Oncology. 25(11). 2277–2284.
12.
Fizazi, Karim, Charles G. Drake, E.D. Kwon, et al.. (2014). Updated Overall Survival (Os) from the Phase 3 Trial, Ca184-043: Ipilimumab (Ipi) Vs Placebo (Pbo) in Patients with Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer (Mcrpc). Annals of Oncology. 25. iv259–iv259.
13.
Slovin, Susan F., Celestia S. Higano, Omid Hamid, et al.. (2013). Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Annals of Oncology. 24(7). 1813–1821.
14.
Rugo, Hope S., Mario Campone, Dino Amadori, et al.. (2013). A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. Breast Cancer Research and Treatment. 139(2). 411–419.
15.
Lebbé, Célèste, Jeffrey S. Weber, Michele Maio, et al.. (2012). Five-Year Survival Rates for Patients (PTS) with Metastatic Melanoma (MM) Treated with Ipilimumab (IPI) in Phase II Trials. Annals of Oncology. 23. ix363–ix364.
16.
Sinha, Devbarna, M. Brent McHenry, Stuart R. Lipsitz, & Malay Ghosh. (2009). Empirical Bayes estimation for additive hazards regression models. Biometrika. 96(3). 545–558.
17.
Wright, Stephen, M. Brent McHenry, William J. Leahey, et al.. (2008). A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus. Lara D. Veeken. 47(2).
18.
Tan, Yan, et al.. (2007). Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathy. American Journal of Physiology-Renal Physiology. 293(4). F1026–F1035.
19.
Lopes‐Virella, Maria F., M. Brent McHenry, Stuart R. Lipsitz, et al.. (2006). Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis. 190(2). 359–369.
20.
Klein, Richard L., M. Brent McHenry, Kerry H. Lok, et al.. (2004). Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: Associations with lipoprotein subclasses. Metabolism. 53(10). 1296–1304.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Victoria Villaflor Breakdown of academic impact, for papers by Sebastiano Buti Breakdown of academic impact, for papers by Guillermo de Velasco Breakdown of academic impact, for papers by Pei He Breakdown of academic impact, for papers by Matthew A. Gubens Breakdown of academic impact, for papers by Brigitte Laguerre Breakdown of academic impact, for papers by Ryuichi Mizuno Breakdown of academic impact, for papers by Davey B. Daniel Breakdown of academic impact, for papers by Wade T. Iams Breakdown of academic impact, for papers by Stefan Diem